UNSPSC 51283963: Phthalylsulfamethizole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C17H14N4O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TAY5ZBM0MO, chemically known as 4-((5-methyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phthalanilic acid but more generally known as phthalylsulfamethizole, which bears US NIH Compound Identifier 3047837. European Medicines Agency schedules Phthalylsulfamethizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09798MIG.

The term PHTHALYLSULFAMETHIZOLE is an International Non-Proprietary Name. PHTHALYLSULFAMETHIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC1SC(NN1)C)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.

UNSPSC 51283963 Phthalylsulfamethizole (Commodity) comprises pharmaceutical products and medical supplies procured by state and local health agencies, emergency services, and cooperative purchasing organizations. Recent solicitations show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative arrangements, and emergency medical and first aid supplies for fire rescue operations. The issuing bodies span county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances; Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent recent activity. Work under the code involves procurement of pharmaceutical products with specific National Drug Codes (NDC), emergency medical consumables (endotracheal tubes, cardiac monitoring electrodes, respiratory equipment, bandaging materials), naloxone kits, and drug deactivation systems, typically with quarterly or annual delivery schedules and compliance requirements including cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, and FDA validation.

Geographic activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include the Seminole County IFB60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies ($700,000 estimated value, sheltered as a certified Small Local Business Enterprise opportunity with a 5% bid discount); the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) effective July 1, 2026; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels. Contracts typically carry one- to two-year initial terms with renewal or extension options and require vendors to maintain insurance coverage, submit detailed product information including NDCs and manufacturing locations, and comply with federal environmental and healthcare regulations.